Arcus Biosciences (RCUS) Misses Q3 EPS by 5c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.11), $0.05 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.46 million versus the consensus estimate of $9.47 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Goldman starts Talen at buy, sees PJM power tightness boosting earnings